Soleno Therapeutics Inc (NAS:SLNO)
$ 57.31 -1.87 (-3.16%) Market Cap: 2.47 Bil Enterprise Value: 2.30 Bil PE Ratio: 0 PB Ratio: 8.89 GF Score: 32/100

Soleno Therapeutics Inc Randomized Withdrawal Period of Study C602 Topline Results Call Transcript

Sep 26, 2023 / 01:00PM GMT
Release Date Price: $26.8 (+504.97%)
Operator

Greetings. Welcome to Soleno Therapeutics randomized withdrawal period of Study C602 topline results. (Operator Instructions) Please note this conference is being recorded.

At this time, I'll now turn the floor over to Brian Ritchie with LifeSci Advisors. Brian, you may now begin.

Brian Ritchie
LifeSci Advisors, LLC - IR

Thank you, operator. Thank you all for joining us this morning. With me on today's call are Soleno's Chief Executive Officer, Dr. Anish Bhatnagar; the company's Chief Financial Officer, Jim Mackaness; and Dr. Jennifer Miller, Professor of Pediatrics in the Division of Endocrinology at the University of Florida. This morning, Soleno issued a news release announcing top-line results from the company's randomized withdrawal period of Study C602, evaluating DCCR tablets for patients with Prader-Willi syndrome.

Please note that certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that, during this call, Soleno management

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot